FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression

FGFR2 identified as key driver in KRAS-mutated pancreatic cancer progression

Precancerous pancreatic lesions and some pancreatic ductal adenocarcinoma (PDAC) tumors harboring KRAS mutations had higher-than-normal expression of the FGFR2 protein, and FGFR2 inactivation delayed KRAS-mutated PDAC development in mice.

First step to slow down the pancreas cancer - Global Happenings

It is possible Slow down growth Of one of the most aggressive tumorsthat of pancreasnow a candidate to become the second killer tumor by 2030 by 2030. AND’ Just a first step because the result was obtained in the laboratory on mice And cells of cellsbut it is finally Found a way to slow down its very rapid growth And so far unstoppable. “A race against time“, The researchers led by David Tuveson, director of the Cold Research Center of Cold Spri…

Inhibiting FGFR2 Supports Prevention and Delay of Common Pancreatic Cancer

Pancreatic ductal adenocarcinoma (PDAC) is the most prevalent type of pancreatic cancer, characterized as a highly lethal malignancy that is often preceded by precancerous lesions. These lesions are relatively common, but only a small portion will progress to PDAC.   In a new study published in Cancer Research titled, “FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development,” researchers from Cold Spring Harbor Laboratory (CSHL)…

Targeting FGFR2 Could Offer Hope in Preventing or Delaying KRAS-Mutated

FGFR2 Abrogation Intercepts Pancreatic Ductal Adenocarcinoma Development In a groundbreaking study published in the journal Cancer Research, researchers have uncovered intriguing insights that could reshape our understanding of pancreatic cancer progression. The focus of the study centers around the FGFR2 protein, with findings suggesting that its expression is markedly heightened in precancerous pancreatic lesions and certain pancreatic ductal …